OpenAI researcher Miles Wang is in talks to leave the ChatGPT maker and launch a new startup focused on AI drug discovery, with discussions reportedly centering on a $200 million raise at a $2 billion valuation. The company would add to a fast-rising wave of startups betting that large AI models can speed up the search for new medicines, identify promising compounds and uncover new uses for existing drugs.
What Wang is planning
According to four people with knowledge of the plans, Wang is preparing a startup focused on developing AI models for drug discovery. Several other OpenAI researchers are expected to join him, signaling that the venture could begin with an unusually research-heavy founding team.
Two of the people said Wang is in talks to raise about $200 million at a $2 billion valuation. Sources also said Lightspeed is in discussions to lead the funding round. The talks are ongoing, however, and the deal may not be final; details could still change.
Wang disputed the story’s funding figures and description of the company, though he did not provide corrected numbers or further specifics. Lightspeed did not respond to a request for comment.
A hot market for AI drug discovery
The reported fundraising talks come as investors continue to show strong appetite for AI applied to life sciences. The field has attracted major capital as backers look for companies that can use machine learning to shorten the long, expensive process of finding and validating drug candidates.
That momentum was underscored this week by Chai Discovery, a two-year-old startup building AI models that can predict molecular interactions to identify new drugs. Chai announced on Tuesday that it had raised $400 million at a $3.8 billion valuation. One of its co-founders, Josh Meier, also worked at OpenAI as a researcher.
Another major milestone came in May, when Isomorphic Labs, the Google DeepMind spinout focused on AI for drug discovery, raised a $2.1 billion Series B. Together, the fundraising rounds show how much investor confidence has built around the idea that AI can contribute meaningfully to pharmaceutical research.
Why existing drugs matter
Sources told TechCrunch that Wang’s startup may be working on AI models designed to find new uses for existing drugs, and possibly for medicines that previously failed in trials. That approach has a practical advantage: repurposing FDA-approved drugs can lead to faster time to revenue than developing a brand-new drug from scratch, because approved medicines have already been tested for safety.
Drug repurposing is not a new idea, but AI could make it more efficient by helping researchers search large datasets, map molecular relationships and generate hypotheses about how compounds might work against different conditions. For startups, that can be especially attractive because it offers a path that may be less capital-intensive and potentially quicker than traditional drug development, while still addressing a huge market opportunity.
Wang’s background at OpenAI
Wang joined OpenAI in 2024 after dropping out of Harvard, where he was pursuing a bachelor’s degree in computer science. His move fits a broader pattern in which investors have once again become comfortable backing young founders who have not completed college, especially in AI.
At OpenAI, Wang co-authored research papers, including work evaluating how AI models can automate and accelerate scientific discovery. That background makes his reported move into drug discovery a logical extension of his prior research interests, even if the company’s exact scope remains unclear.
Why the deal is drawing attention
If the fundraising terms are accurate, Wang’s new company would debut with an unusually high valuation for an early-stage startup. A $2 billion price tag before a product has been publicly launched would reflect strong conviction from investors about the commercial promise of AI in drug discovery, as well as confidence in the team assembling around him.
The reported interest also highlights the continued influence of OpenAI alumni in the broader startup ecosystem. Several companies in the AI and biotech intersection have been founded or led by people with OpenAI backgrounds, and investors appear increasingly willing to fund them at large scale.
Key reported details
- Miles Wang is an OpenAI researcher whose work has included using AI to accelerate scientific and biological discovery.
- He is reportedly leaving OpenAI to launch an AI drug discovery startup.
- Several other OpenAI researchers are expected to join the company.
- The startup is in talks to raise about $200 million at a $2 billion valuation.
- Lightspeed is reportedly in discussions to lead the round.
- Wang disputed the funding figures and company description but did not offer corrected details.
The broader implications
AI drug discovery remains a field full of promise and uncertainty. Supporters argue that modern models can help researchers understand complex biological systems at scale, speed up candidate identification and reduce wasted effort in early-stage research. Skeptics note that promising computational results do not always translate into approved therapies, and that drug development still depends on long, expensive clinical testing.
Still, the pace of investment suggests that many venture firms believe the opportunity is large enough to justify the risk. If Wang’s startup does move forward with major funding, it would join a small but increasingly prominent group of companies trying to use AI not just to improve software or productivity, but to reshape how medicines are discovered.
Explore more: Blog Our Services Contact Us
Source: Original report
Was this helpful?
Last Modified: July 15, 2026 at 6:38 pm
2 views
